OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
June 22 2023 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision
medicine company harnessing the power of molecular diagnostics and
bioinformatics to help combat infectious disease, reported that its
German subsidiary, Curetis GmbH, has received the full set of ten
Unyvero A30 C-Series instruments, which have been assembled by its
development partner, DMTPe, in Germany. The instruments have
successfully passed electrical and functional testing and will
allow rapid sample-to-answer molecular testing with numerous
chemistries and assay formats.
These C-Series instruments incorporate all
learnings from extensive testing of the 10 B-Series instruments
over the past 12 months. The C-Series instruments have been
optimized and improved for manufacturability, serviceability and
robustness. They have also been optimized for extended lifetime of
all key moving parts inside the instruments, as well as cost of
goods in the manufacturing process of these A30 instruments.
Andreas Boos, CTO of Curetis and program lead of
the Unyvero A30 platform project commented: “We are excited to have
taken possession of this newest batch of instruments. With all of
the improvements made to date, this is now very close to the final
release version of the product. We intend to use the A30 C-Series
instruments in all further product development and clinical trials
as well as regulatory submissions for our application cartridges on
the A30 system.” Mr. Boos added that, “all of our ten B-Series
instruments have also been upgraded to this latest standard to plan
for sufficient A30 instruments to be available for the continued
development of our own assays and cartridges in house, and for
collaborative projects such as the FIND R&D collaboration which
aims to bring an A30 platform and antimicrobial resistance (AMR)
test from blood cultures to low and middle income countries, as
well as for other R&D collaboration projects funded by third
party partners.”
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, U.S.A.) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with our subsidiaries, Curetis GmbH and Ares
Genetics GmbH, we are developing and commercializing molecular
microbiology solutions helping to guide clinicians with more rapid
and actionable information about life threatening infections to
improve patient outcomes, and decrease the spread of infections
caused by multidrug-resistant microorganisms, or MDROs. OpGen’s
current product portfolio includes Unyvero, Acuitas AMR Gene
Panel, and the ARES Technology Platform including ARESdb, NGS
technology and AI-powered bioinformatics solutions for antibiotic
response prediction including ARESiss, ARESid, ARESasp, and
AREScloud, as well as the Curetis CE-IVD-marked PCR-based
SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
OpGen’s C-Series Unyvero A30 instruments. These
statements and other statements regarding OpGen’s future plans and
goals constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and are intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
the success of our commercialization efforts, our ability to
successfully, timely and cost-effectively develop, seek and obtain
regulatory clearance for and commercialize our product and services
offerings, the rate of adoption of our products and services by
hospitals and other healthcare providers, the fact that we may not
effectively use proceeds from recent financings, our ability to
satisfy debt obligations under our loan with the European
Investment Bank, the effect of the military action in Russia and
Ukraine on our distributors, collaborators and service providers,
our liquidity and working capital requirements, the effect on our
business of existing and new regulatory requirements, and other
economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Investor & Press Contact:Alyssa
FactorEdison Groupafactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024